Related Experiment Videos
Role of interferons in the therapy of metastatic renal cell carcinoma
1Oncology Center for I.V. Therapies and Cancer Therapeutics, Houston, Texas.
Abstract:
The prognosis of metastatic renal cell carcinoma continues to be dismal because of the lack of effective systemic therapies. To date, existing chemotherapy and hormonal therapy have produced disappointing results. However, alpha interferon and other biologic response modifiers have recently shown evidence of modest but consistent activity. This review summarizes results obtained with alpha interferon alone or in combination in the treatment of advanced renal carcinoma. It is hoped that future development of this field of cancer therapy may result in further improvements in the clinical management of these patients.
Insights
Metastatic renal cell carcinoma has a poor prognosis due to limited effective treatments. Alpha interferon shows modest but consistent activity, offering hope for improved therapies in advanced renal carcinoma.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Metastatic renal cell carcinoma (mRCC) has a historically poor prognosis.
- Conventional chemotherapy and hormonal therapies have yielded limited success in treating mRCC.
Purpose of the Study:
- To review the efficacy of alpha interferon in treating advanced renal carcinoma.
- To summarize findings on alpha interferon, alone or in combination therapy.
Main Methods:
- Review of existing studies on alpha interferon for advanced renal carcinoma.
- Analysis of treatment outcomes with alpha interferon-based regimens.
Main Results:
- Alpha interferon demonstrates modest but consistent activity in advanced renal carcinoma.
- Biologic response modifiers, including alpha interferon, show potential in mRCC treatment.
Conclusions:
- Alpha interferon offers a promising avenue for managing advanced renal carcinoma.
- Further research into alpha interferon and related therapies may enhance clinical outcomes for mRCC patients.